AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03583645 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
Study NCT03885466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking exercise
Description: Participants will initially train 3 times per week for 3 months. Training sessions will be led by trained peer- and/or student-instructors. Nordic walking sessions (starting at 20 and progressing to 60min/session) will include a warm-up, strengthening, and dynamic balance and stretching exercises in addition to Nordic walking, as per the Saskatoon Health Region guide (Saskatoon Health Region, 2014). Training (distance and intensity) will be progressive and individually set.
Study NCT01320423 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Trial
Description: Surgical Trial in Lobar Intracerebral Haemorrhage
Study NCT02028832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIM consult and service provision
Description: If service is requested, treatment options include acupuncture/acupressure, massage, and reiki
Study NCT02028832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.
Study NCT02028832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.
Study NCT01978366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state
Study NCT03030937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
Study NCT03030937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan was used as second line treatment with AGC.
Study NCT03030937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was used as second line treatment with AGC.
Study NCT01676948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Study NCT01676948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study NCT01676948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.~Canakinumab-naïve patients
Study NCT01676948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
Study NCT04959201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE plus AO
Description: Use of an NMDA enhancer plus a drug with antioxidant property for the treatment of schizophrenia.
Study NCT03233178 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Study NCT04959201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NMDAE plus Placebo Cap
Description: Use of an NMDA enhancer plus placebo as a comparator.
Study NCT03791502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Method Exercises
Description: Pilates Method exercises performed on the apparatus, on the ground and with accessories. They will always be performed by a physiotherapist with teaching certification in the Pilates methodology and will be supervised by two properly trained physiotherapy trainees. Participants will start the exercise program in small groups of up to 8 people, twice a week for 60 minutes, for 12 weeks, totaling 24 sessions. The first day of intervention for both groups will be devoted to explaining the six principles described by Joseph Pilates: centralization, concentration, control, precision, fluidity and breathing, and some fundamentals such as the neutral position of the spine. And in all sessions, these principles will be remembered by the physiotherapist.
Study NCT00502034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2a
Description: Interferon Alfa-2a in combination with Interleukin
Study NCT00502034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interferon Alfa-2a in combination with Interleukin
Study NCT02067234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care/Education
Description: Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.
Study NCT02067234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation/Coping Prevention
Description: In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
Study NCT04141735 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: no intervention
Study NCT02477280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Cross-over
Study NCT02477280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: Cross-over
Study NCT02477280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Medikinet
Study NCT02477280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medikinet
Study NCT03253016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaginal swab -microbiome test and blood test for cytokines
Description: vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms
Study NCT02281526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093
Study NCT00171873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR (Long-acting release)
Description: 30 mg intramuscularly every 28 days
Study NCT00171873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride intramuscularly every 28 days
Study NCT04815317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditive stimulation
Description: The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes.
Study NCT04815317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensitive stimulation
Description: Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes.
Study NCT04815317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auditory control
Description: The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise.
Study NCT04815317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensitive control
Description: The sensitive control condition will be achieved by administering fresh air on the calf.
Study NCT02891343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-hour period of hypoxia
Description: During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.
Study NCT02041923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: H-HOPE
Description: Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.
Study NCT02041923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
Study NCT02750176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed chain exercises
Description: Closed-chain strengthening will be performed with the shoulder moving over a fixed hand. Resistance will be provided by body weight against gravity. To off-load and progress the amount of body-weight resistance, elastic bands will be used to support body weight using a exercise frame. Patients will perform 6 exercises.
Study NCT02956434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Family Intervention
Description: Two 50-minute sessions aimed at helping family members be most supportive to their loved one's treatment goals.
Study NCT03970993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination
Description: Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly
Study NCT03970993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination and CHMI
Description: Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite
Study NCT03970993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination booster
Description: Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule
Study NCT03346213 — intervention group
Intervention type: DRUG
Intervention: MonoFer
Description: Anaemic patients undergoing major surgery who would routinely be receiving intravenous iron 'MonoFer' will get this as part of routine care. They will then have a CPET repeated at least 10 days afterwards.
Study NCT00621296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424 (Telaprevir)
Description: Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
Study NCT03443713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM
Description: Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
Study NCT03374657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPK850
Description: In one of 4 dose levels administered via subretinal injection under anesthesia
Study NCT01754363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attune Primary Total Knee Replacement
Description: Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
Study NCT03390504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
Study NCT03390504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: Participants will receive vinflunine 320 mg/m\^2 as a 20-minute intravenous infusion.
Study NCT03390504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion.
Study NCT03390504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.
Study NCT03390504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
Description: FGFRi CTA will be used to determine molecular eligibility.
Study NCT02919592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MemoryShape® Breast Implants
Description: MENTOR® MemoryShape™ Breast Implants are devices with shells constructed from medical grade silicone elastomer. The shell is filled with Mentor's proprietary formulation of medical grade silicone gel. The textured shell is constructed of successive crosslinked layers of silicone elastomer, and includes raised orientation marks on the anterior and posterior of the implant intended to help the physician orient the implant and ensure proper placement during implantation. Each MENTOR® MemoryShape™ Breast Implant is provided sterile. MemoryShape Breast Implants are available in sizes ranging from 120 cc-775 cc and 5 styles with various projection and height options.
Study NCT02919592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MemoryGel® Breast Implants
Description: MENTOR® MemoryGel™ Breast Implants are round devices with shells constructed from medical grade silicone elastomer. The shell is filled with MemoryGel™, Mentor's proprietary formulation of medical grade silicone gel, and is constructed of successive cross-linked layers of silicone elastomer. There are two styles of shell: smooth and textured. Each MENTOR® MemoryGel™ Breast Implant is provided sterile. MemoryGel Breast Implants are available in sizes ranging from 100 cc-800 cc and 4 styles with various projection and height options.
Study NCT02919592 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Other Aesthetic Surgery
Description: Other aesthetic surgery procedures (for example, liposuction, rhinoplasty, brow lift, rhytidectomy, mentoplasty/genioplasty, otoplasty, or blepharoplasty; may not include silicone implants)
Study NCT03652064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.
Study NCT03652064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.
Study NCT03652064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.
Study NCT03652064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.
Study NCT03652064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.
Study NCT03652064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.
Study NCT03652064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.
Study NCT03314740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Comparator active compound
Study NCT03314740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Experimental compound
Study NCT03314740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Experimental compound
Study NCT00880308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Study NCT02649062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Study NCT02649062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04491292 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT01439659 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional Counseling
Description: Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
Study NCT01439659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Supplements
Description: Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
Study NCT02320643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seratom® PA mesh
Description: Partially absorbable mesh
Study NCT03387202 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic lateral suspension with mesh
Description: V-shaped ccm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3cmsuperoposterior to the anteriosuperior iliac spine.A grasper is introduced retroperitoneally through the subperitoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Broad ligament is lifted upward and tunnel is practiced in its lower third.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level
Study NCT03387202 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal ultrasound
Description: Vaginal length, bladder neck mobility and pelvic floor biometry with anterioposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative first third and sixth months if available.
Study NCT04235582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App + Inputs Contingency Management
Description: The app has programmed contingencies whereby incentives can be earned for behaviors that are inputs to abstaining from drug use (e.g., attending psychotherapy or taking SUD psychopharmacology).
Study NCT04235582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App + Outcomes Contingency Management
Description: The app has programmed contingencies whereby incentives can be earned for outcomes of abstaining from drug use (e.g., drug-negative saliva samples on saliva opioid tests).
Study NCT04513951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: phase II
Study NCT04513951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-leucovorin
Description: phase II
Study NCT04513951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: phase II
Study NCT04513951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: phase II
Study NCT04513951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: phase II
Study NCT04513951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: phase II
Study NCT02845375 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Neostigmine
Description: Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
Study NCT02845375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.